Immunic presents clinical and preclinical data for imu-856 at digestive disease week 2023, including its molecular mode of action

– imu-856 is an orally available, systemically acting, highly selective and potent small molecule modulator of sirt6 – – targets regeneration of bowel epithelium and restoration of intestinal barrier function – – builds on recently released phase 1b data showing beneficial effects in celiac disease histology, disease symptoms, biomarkers and nutrient absorption – – virtual eposter to be presented today, may 6, 2023, during 9:30 am - 4:00 pm ct poster session – new york , may 6, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of clinical and preclinical data for imu-856. included in this presentation are new data on imu-856's mode of action as a potent modulator of sirt6 (sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.
IMUX Ratings Summary
IMUX Quant Ranking